Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research

The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.

Time to say good bye message with wood - Image

More from Earnings

More from Business